qli5 therapeutics logo

qli5 therapeutics

Pioneering a breakthrough in proteasome inhibitors with unmatched selectivity and innovative, non-covalent binding properties.

1 employees · est. 2020

VS
Totus Medicines logo

Totus Medicines

Making every disease treatable by making the total human genome druggable.

33 employees · est. 2020 · Emeryville, United States

Totus Medicines is the larger of the two.

Side-by-Side Comparison

qli5 therapeutics Totus Medicines
Founded
2020 2020
Headquarters
Not tracked yet Emeryville, United States
Employees
1 33 larger
Industry
Health and Wellness Biopharma, Biotechnology
Funding Stage
Series A Series B
Total Funding
$15.00M $107.00M
Funding Rounds
2 4
Services
Development of next-generation proteasome inhibitors, Research collaboration with Max Planck Institute, Platform technology for unmet medical needs Development of precision oral medicines, Targeting undruggable disease-relevant targets, Advancement of small-molecule therapies
Target Customers
Healthcare providers, Pharmaceutical companies, Biotech researchers, Cancer treatment centers, Patients with multiple myeloma, Patients with solid tumors Patients with limited treatment options, Healthcare providers in oncology, immunology, and inflammation sectors
Taxonomy
Proteasome Inhibitors, Selective Inhibition, Non-Covalent Binding, Therapeutics Development, Pharmaceutical Innovation, Drug Discovery, Targeted Therapy, Oncology Research, Molecular Medicine, Advanced Biomedicine Chemical Biology, Covalent Therapeutics, Drug Discovery, Genomic Medicine, Untreatable Diseases, Covalent Drugs, Drug Screening, Undruggable Targets, Pharmaceutical Innovation, Precision Medicine, Target Identification, Therapeutic Development
Website
qli5tx.com totusmedicines.com
qli5 therapeutics logo

About qli5 therapeutics

Qli5 Therapeutics, founded in 2020, is forging new pathways in the Health and Wellness industry by developing an innovative class of proteasome inhibitors. Their approach uniquely combines high selectivity with non-covalent binding properties, setting them apart in the field. The startup's slogan,...

Totus Medicines logo

About Totus Medicines

Totus Medicines, founded in 2020, is an emerging leader in the Biopharma and Biotechnology sectors, headquartered in the United States. The company is committed to its bold vision of "Making every disease treatable by making the total human genome druggable." By leveraging groundbreaking chemical bi...

Be first to know when either one moves

Funding rounds, hiring surges, leadership changes and stack switches at qli5 therapeutics and Totus Medicines — tracked continuously, sent the day they land.

Watch both — free

Funding, hiring, leadership and stack changes at qli5 therapeutics and Totus Medicines — by email.

Frequently Asked Questions

qli5 therapeutics — Pioneering a breakthrough in proteasome inhibitors with unmatched selectivity and innovative, non-covalent binding properties.. Totus Medicines — Making every disease treatable by making the total human genome druggable.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
qli5 therapeutics has raised $15.00M while Totus Medicines has raised $107.00M.
qli5 therapeutics and Totus Medicines operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare qli5 therapeutics with someone else

Start typing a company name or domain.

One analytics cookie (Google Analytics). Cookie Policy